No change
Add to watchlist
Create an alert
Stocks and Shares ISATScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.
Company Information
About this company
Key people
Gavin Macbeath
Chief Executive Officer, Director
Jason A. Amello
Chief Financial Officer, Treasurer
Chrystal U. Louis
Chief Medical Officer
Zoran Zdraveski
Chief Legal and Strategy Officer, Secretary
Stephen R. Biggar
Independent Non-Executive Chairman of the Board
Katina Dorton
Independent Director
Gabriela Gruia
Independent Director
Barbara J. Klencke
Independent Director
Garry A. Nicholson
Independent Director
Click to see more
Key facts
- Shares in issue52.47m
- EPICTCRX
- ISINUS89854M1018
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$66.40m
- Employees146
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.